louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05932940: Incidence of Descemet Membrane Detachment Post GATT by AS OCT
Official title: Incidence of Descemet Membrane Detachment Post Gonioscopy-Assisted Transluminal Trabeculotomy by Anterior Segment Optical Coherence Tomography in Patients With Open Angle Glaucoma
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Angle Glaucoma Open
Keywords: gonioscopy-assisted transluminal trabeculotomy
Descemet membrane detachment
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-07-06
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: detection of incidence of Descemet membrane detachment post gonioscopy-assisted transluminal trabeculotomy by anterior segment optical coherence tomography in patients with open angle glaucoma.
Primary purpose: DIAGNOSTIC

Brief summary: detection of Incidence of Descemet membrane detachment post gonioscopy-assisted transluminal trabeculotomy by anterior segment optical coherence tomography in patients with open angle glaucoma.

Detailed description: In our study, which should include 30 eyes with OAG who underwent 360 GATT Screening for Descemet Membrane Detachment will be done by Anterior Segment Optical coherence Tomography using SD-OCT: Optovue RTVue (Optovue Inc., Fremont, CA, USA) for the angle day 1 post operative for all patients and 1 week post operative in cases with Descemet membrane detachment to check for spontaneous resolution.

One month post-operative the patients underwent

* Best corrected visual acuity (BCVA) using decimal.
* IOP measurement using GAT.

Eligibility criteria: Inclusion Criteria:

1. Age 18 - 70 years.
2. Patients with open angle glaucoma undergoing gonioscopy assisted transluminal trabeculotomy.

Exclusion Criteria:

1. Patients with with open angle glaucoma and aphakia.
2. Patients with Congenital Glaucoma.
3. Patients with open angle glaucoma undergoing phaco -gonioscopy-assisted transluminal trabeculotomy.
4. Patients with neovascular glaucoma.
5. Patients with pigmentary Glaucoma.

Primary outcomes:
measure: Incidence of Descemet Membrane detachment post GATT
timeFrame: 4 months
Secondary outcomes:
measure: Amount of reduction of IOP and Glaucoma NGM
timeFrame: 4 months
measure: Incidence of Hyphema post GATT
timeFrame: 4 months
measure: Incidence of Descemet membrane detachment post gonioscopy-assisted transluminal trabeculotomy by anterior segment optical coherence tomography in patients with open angle glaucoma.
timeFrame: 4 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Facility of medicine , Cairo University
state: Almanial
Study officials:
affiliation: Cairo University
name: Fayrouz Aboalazayem, phD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00172640: Genetic Studies in Liver Cancer Patients
Official title: Identification of Differentially Expressed Genes in Hepatocellular Carcinoma With DNA Microarrays
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hepatocellular Carcinoma
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
Collaborators: name: Industrial Technology Research Institute, Taiwan
First posted: 2005-09-15
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: Hepatocellular carcinoma (HCC) is one the most common malignancies in the world, especially in sub-Saharan Africa and Southeast Asia. Since 1984, it has been the leading cause of cancer death in Taiwan. About 6000-8000 people died of this cancer every year in Taiwan. DNA microarray (DNA chip) is a very powerful tool to clarify the genetic changes in cancers. Expression profiling techniques have been used to simultaneously monitor the expression of thousands of genes from human tumor samples. It has been successfully used to predict clinical outcome and survival as well as classify different types of cancer. In this study, we will use the DNA chip to study the genetics in liver cancer patients.

Detailed description: The clinical samples will be collected in the NTUH, while the DNA microarray works will be done in Biomedical Engineering Center (BMEC) of ITRI.

Patients A total of 40 cases of HCC patients (20 HBV-related HCC and 20 HCV-related HCC) who received surgical resection in National Taiwan University Hospital will be enrolled from our tissue banks. The diagnosis of HCC was confirmed by pathological examination. The surgical specimens were frozen immediately after surgery and stored in -140°C. The clinicopathological data will be retrospectively obtained from chart reviews.

Another total of 40 new HCC patients who receive surgical resection in National Taiwan University Hospital will be collected. The healthy subjects and patients chronically infected with HBV or HCV without HCC will be used as controls. The whole bloods will be collected before, one and six months after operation. The diagnosis of HCC will be confirmed by pathology. In addition to the whole bloods, the surgical specimens will be frozen immediately after surgery and stored in -140°C.

Eligibility criteria: Inclusion Criteria:

* hepatocellular carcinoma

Exclusion Criteria:

* multiple cancers

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Chien-Hung Chen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06442540: Effects of Intra Muscular Electrotherapy Combined With Manipulative Therapy in Patients With Sacral Torsion
Official title: Effects of Intra Muscular Electrotherapy Combined With Manipulative Therapy in Patients With Sacral Torsion
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Sacroiliac Joint Dysfunction
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2024-06-04
Enrollment: 32
Sex: ALL
Minimum age (years): 22
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized Controlled Trial
Primary purpose: TREATMENT

Brief summary: This study is a randomised controlled trial and the purpose of this study is to determine the effect of intra muscular electrotherapy combined with manipulative therapy in terms of pain, mobility, range of motion, and disability."

Detailed description: The purpose of this study is to determine the effect of intra muscular electrotherapy combined with manipulative therapy in terms of pain, mobility, range of motion, and disability in patients with sacral torsion." (age : 22-44 years )

1. Numeric pain rating scale
2. Inclinometer Lumbar Flexion
3. Oswestry Disability Questionairre
4. Goniometer SLR ROM Data will be collected before and after the intervention protocol for each participant.

Data collection procedure: Participants of interest would be approached and explained about the research. Informed written consent will be taken. Pre and post intervention scores will be recorded.

Eligibility criteria: Inclusion criteria:

* Age group: 22-44 years old
* Both males and females
* Clinically diagnosed sacral torsion
* Patients with pain intensity of at least 5 on NPRS
* Positive backward bent test
* Positive forward bent test
* Uneven Sacral sulcus
* Uneven ILA of sacrum
* Piriformis syndrome

Exclusion criteria :

* Any congenital deformities
* Demonstrated neurological deficit.
* Pregnant females
* History of spinal surgery
* Spondylolisthesis
* Severe lumbar spondylosis
* Spinal stenosis
* Serious spinal conditions like infection, tumors, osteoporosis, spinal fracture
* osteoporosis

Primary outcomes:
measure: Pain Intensity
timeFrame: 4 weeks
measure: Lumbar ROM
timeFrame: 4 weeks
measure: SLR ROM
timeFrame: 4 weeks
measure: Level of Disability
timeFrame: 4 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Foundation University College of Physical Therapy
state: Punjab
Study officials:
References:
Clinical trial NCT00036140: Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Multiple Myeloma
Keywords: Pharmacia
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2002-05-09
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The primary goal of the study is to determine the best dose of an investigational drug to give to patients with multiple myeloma and to evaluate the investigational drug's effectiveness as a treatment for multiple myeloma.


Eligibility criteria: Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.

Inclusion Criteria:

* Eligible patients must be at least 18 years of age with a diagnosis of multiple myeloma including elevated M-blood/urine protein or a tumor that can be evaluated by the doctor during the investigational drug's treatment.
* The patient's multiple myeloma must have gotten worse during/after previous chemotherapy was given.
* Any side-effects from prior chemotherapy must have subsided
* Blood and urine tests must show adequate bone marrow, liver, and kidney function.

Exclusion Criteria:

Any of the following will exclude patients from study participation:

* indolent or smoldering myeloma or localized plasmacytoma
* hyperviscosity syndrome
* irradiation to 25% or more of bone marrow
* prior high dose chemotherapy with bone marrow or stem cell support
* current participation in other clinical trials
* pregnant or breast-feeding women
* known HIV-positive or AIDS-related illness
* patients planning to have radiation therapy or surgery that would interrupt study therapy in the next 6 months.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Research Center
state: California
city: Los Angeles
country: United States
facility: Research Center
state: California
city: Rancho Mirage
country: United States
facility: Research Center
state: California
city: Cleveland
country: United States
facility: Research Center
state: Ohio
city: Marshfield
country: United States
facility: Research Center
state: Wisconsin
Study officials:
References:
Clinical trial NCT02997540: Effect of Body Position and Probe Position on the Localization of Breast Mass
Official title: Evaluation of the Effect of Body Position and Probe Position on the Localization of Breast Mass in Free-Hand Breast Ultrasound Examination
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Breast Diseases
Keywords: female breast lesion
ultrasound examination
Lead sponsor: MetriTrack, Inc.
Sponsor class: INDUSTRY
First posted: 2016-12-20
Enrollment: 20
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Females of any ethnic group who meet all inclusion and none of the exclusion criteria will be eligible for enrollment

Brief summary: The purpose of this study is to demonstrate that BVN G-1000 can precisely and consistently measure the position of female breast lesions regardless of patient rotation and probe angle during ultrasound examination.

Detailed description: The proposed research consists of quantitatively detecting and reporting the effect of body rotation and ultrasound probe position on the breast on the position of breast lesions relative to the breast nipple and body orientation planes, required for positional annotations, in female subjects at one study visit. Measurements will be manually and automatically recorded by two ultrasound operators with each image and will be compared among these conditions to detect effects of probe position and probe orientation and patient's body position relative to the exam table. The manual and automated measurements will be compared to determine the differences between the data obtained using the two different methods.

Eligibility criteria: Inclusion Criteria:

1. Female
2. 21-70 years of age
3. Known palpable or non-palpable benign or probably benign breast mass or masses, less than 2 cm in maximum diameter and at least 4 cm away from the nipple, from a previous ultrasound examination

Exclusion Criteria:

1. Women with cardiac pacemaker or portable defibrillator
2. Women with known breast cancer or suspicious lesions
3. Pregnant and lactating women
4. Women who have breast implant(s)
5. Women who have had prior breast surgical intervention not including breast needle biopsy, in the same breast with the qualifying target mass.
6. Women with the target finding to be mapped within a distance of 4 cm from patient's nipple.
7. Women with multiple similar qualifying targets in close proximity (less than 4 cm between targets).
8. Women with history of allergy to medical-grade adhesive tape or ultrasound gel
9. Women whose weight is over 250 pounds

Primary outcomes:
measure: movement of a given ultrasound breast lesion
timeFrame: study completion, an average of 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Evanston
country: United States
facility: Evanston Hospital
state: Illinois
Study officials:
References:
Clinical trial NCT03070340: Comparison of MRI and CEDM to Evaluate Treatment Response Before Surgery
Official title: Comparison of Breast Magnetic Resonance Imaging (MRI) and Contrast Enhanced Mammography (CEDM) to Evaluate Residual Disease Extent After Neoadjuvant Therapy (NAT)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Keywords: mastectomy
breast MRI
contrast enhanced mammography
CEDM
17-045
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2017-03-03
Enrollment: 125
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to compare the diagnostic accuracy of breast magnetic resonance imaging (MRI) and contrast enhanced digital mammography (CEDM) in assessing the residual disease extent in patients who have completed neoadjuvant therapy (NAT).


Eligibility criteria: Inclusion Criteria:

* Any woman who has completed or is nearing completion of neoadjuvant therapy for breast cancer and is scheduled for a post-NAT breast MRI and mammogram
* Surgery (mastectomy or BCT) planned within 60 days of the MRI

Exclusion Criteria:

* Women who have a contraindication to the intravenous use of iodinated contrast agent (i.e., allergy to iodinated contrast or severely impaired renal function with a creatinine level \> 1.3 or eGFR ≥45)
* Known allergic reaction to gadolinium; patient may be eligible if the referring physician determines that the MRI is medically necessary and if the patient is willing to undergo pre-medication for contrast allergy
* Pregnant women
* Male patients
* Presence of non MR compatible metallic objects or metallic objects that, in the opinion of the radiologist, would make MRI a contraindication
* Known or suspected renal impairment. Requirements for GFR prior to MRI as determined by local site standard practice
* Women who have already had their standard of care post-NAT mammogram and/or breast MRI

Primary outcomes:
measure: Compare diagnostic accuracy of breast MRI and CEDM
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Basking Ridge
country: United States
facility: Memorial Sloan Kettering Basking Ridge (Consent only)
state: New Jersey
city: Montvale
country: United States
facility: Memorial Sloan Kettering Bergen (Consent only)
state: New Jersey
city: Commack
country: United States
facility: Memorial Sloan Kettering Commack (Consent only)
state: New York
city: Harrison
country: United States
facility: Memorial Sloan Kettering Westchester (Consent only)
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Janice Sung, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05380167: Efficacy Long-term Dietary Nitrate Consumption to Plasma Nitrite Conversion
Official title: Efficacy and Variability in Plasma Nitrite Levels During Long-term Supplementation With Nitrate Containing Beetroot Juice
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiovascular Diseases in Old Age
Keywords: beetroot juice
dietary nitrate
plasma nitrite
Lead sponsor: Wake Forest University
Sponsor class: OTHER
First posted: 2022-05-18
Enrollment: 13
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be randomized into one of two groups. The first group will consume daily beetroot juice containing 380 mg of nitrate and the second group will consume daily beetroot juice with nitrate removed.
Primary purpose: BASIC_SCIENCE

Brief summary: The objective of this study was to determine the chronic effects of beetroot juice supplementation on the acute (90-minute post nitrate consumption) efficacy of converting dietary nitrate to plasma nitrate and plasma nitrite in healthy middle-to-older aged adults. the investigators were also interested in determining the effect of this intervention on fasting levels of plasma nitrate and nitrite over time. Furthermore, the number of participants classified as "non-responders" was determined based on increases in plasma nitrite achieved using tolerable volumes of beetroot juice by other studies.


Eligibility criteria: Inclusion Criteria:

* Middle and Older (40-80 year-old) men and women
* Body mass index between 18.5 - 30.0 kg/m2
* Able to provide own transportation to study testing visits
* Able to consume study beverages
* Able to speak and read English

Exclusion Criteria:

* Tobacco user (smoke or chew), including e-cigarettes
* Known conditions of: diabetes mellitus (type 1 or 2), atrophic gastritis, hypo- or hyperthyroidism, gout, history of kidney stones, history of hypotension, cardiovascular disease, chronic obstructive pulmonary disease, inflammatory bowel diseases, impaired liver or kidney function
* Current or recent (last 3 months) treatment for cancer
* Current use of the following medications: Phosphodiesterase type 5 inhibitors, nitroglycerin or nitrate preparations, proton pump inhibitors, medication for hypothyroidism, antacid and heartburn medications

Primary outcomes:
measure: Fasting Plasma Nitrate
timeFrame: Collected at baseline (week 0), end of week 1, week 2, week 3, week 4, week 8, and week 12
measure: Fasting Plasma Nitrite
timeFrame: Collected at baseline (week 0), end of week 1, week 2, week 3, week 4, week 8, and week 12
measure: 90 minute plasma Nitrate
timeFrame: Collected at baseline (week 0), end of week 1, week 2, week 3, week 4, week 8, and week 12
measure: 90 minute plasma Nitrite
timeFrame: Collected at baseline (week 0), end of week 1, week 2, week 3, week 4, week 8, and week 12
Secondary outcomes:
Other outcomes:
Locations:
city: Winston-Salem
country: United States
facility: Wake Forest University
state: North Carolina
Study officials:
References:
Clinical trial NCT00575367: Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers
Official title: A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Tears of Healthy Volunteers Following a Single Ocular Administration
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Bacterial Infections
Eye Infections
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2007-12-18
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to evaluate the drug concentrations of AzaSite compared to Vigamox in tears of healthy volunteers


Eligibility criteria: Inclusion Criteria:

* Have visual acuity, using corrective lenses (no contact lenses) if necessary, in both eyes of at least +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study.
* Have normal lid anatomy.

Exclusion Criteria:

* Have an abnormal biomicroscopy or ophthalmoscopy exam.
* Have a diagnosis of dry eye disease or have experienced any of the dry eye symptoms (photophobia, foreign body sensation, itching, burning, pain, dry or grittiness) in the past thirty days.
* Have used artificial tears in the past thirty days.
* Have a diagnosis of on-going ocular infection or lid margin inflammation.
* Have ever had penetrating ocular surface or intraocular surgery.
* Have a known hypersensitivity to azithromycin, or any macrolide antibiotic or to any of the ingredients in AzaSite.
* Have had a known hypersensitivity to Vigamox or any fluoroquinolone antibiotics or to any of the ingredients in Vigamox.
* Have had corneal or lid abnormalities.
* Have glaucoma, or Intra Ocular Pressure of 22 mm Hg or greater in one or both eyes.
* Have any ocular pathology with the exception of cataracts.
* Have a serious systemic disease or uncontrolled medical condition.
* Have experienced symptoms of viral or allergic conjunctivitis in the past 30 days.
* Have a history of liver or kidney disease resulting in persisting dysfunction.

Primary outcomes:
measure: Concentration of AzaSite and Vigamox in the Tear Fluid Across Six Time Points Ranging From 15 Minutes to 24 Hours Following Administration.
timeFrame: 15 minutes, 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Mount Sinai School of Medicine
state: New York
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Reza Haque, MD
role: STUDY_DIRECTOR
References: